LEADER 03448nam 2200757 a 450 001 9910451234103321 005 20220131184436.0 010 $a1-281-29150-1 010 $a9786611291501 010 $a1-84714-198-6 035 $a(CKB)1000000000415606 035 $a(EBL)436891 035 $a(OCoLC)228657794 035 $a(SSID)ssj0000176711 035 $a(PQKBManifestationID)11922902 035 $a(PQKBTitleCode)TC0000176711 035 $a(PQKBWorkID)10206031 035 $a(PQKB)10357398 035 $a(MiAaPQ)EBC436891 035 $a(Au-PeEL)EBL436891 035 $a(CaPaEBR)ebr10224610 035 $a(CaONFJC)MIL129150 035 $a(OCoLC)893334517 035 $a(EXLCZ)991000000000415606 100 $a19990106d1999 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aImagining insiders$b[electronic resource] $eAfrica and the question of belonging /$fMineke Schipper 210 $aLondon ;$aNew York $cCassell$d1999 215 $a1 online resource (240 p.) 225 1 $aLiterature, culture, and identity 300 $aDescription based upon print version of record. 311 $a0-304-70478-4 311 $a0-304-70479-2 320 $aIncludes bibliographical references (p. [198]-216) and index. 327 $aContents; Acknowledgements; 1 Insiders and outsiders; 2 Homo caudatus: European imagination and its cultural outsiders; 3 The white man has no friends': The European Other in African oral and written literatures; 4 African roots and American black culture; 5 Negritude, Black Consciousness and beyond; 6 Black is beautiful or the whiteness of feminism; 7 Emerging from the shadows: Changing patterns in gender matters; 8 Knowledge is like an ocean: Insiders, outsiders and the academy; 9 Towards a culture of interdiscursivity; Interviews; Bibliography; Index 330 $aThis study surveys a wide range of writings and ideas out of Africa by people of African descent on the various ways in which ""insiders"" and ""outsiders"", ""self"" and ""otherness"" have been imagined and defined from African perspectives. Attention is focused on identity issues regarding Africa, Panafricanism, American Black culture, Negritude and Black Consciousness, as well as on whiteness and otherness, black versus white cultures and gender matters in a racialized context. Some theoretical issues in the academic debate on insiders and intercultural dialogue are also discussed, with exa 410 0$aLiterature, culture, and identity. 606 $aRace 606 $aDifference (Psychology) 606 $aCivilization, Western$xAfrican influences 606 $aWhite people in literature 606 $aAfricans$xRace identity 606 $aAfrican Americans$xRace identity 606 $aSexism 607 $aAfrica$xCivilization$xWestern influences 608 $aElectronic books. 615 0$aRace. 615 0$aDifference (Psychology) 615 0$aCivilization, Western$xAfrican influences. 615 0$aWhite people in literature. 615 0$aAfricans$xRace identity. 615 0$aAfrican Americans$xRace identity. 615 0$aSexism. 676 $a305.8 700 $aSchipper$b Mineke$0657183 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451234103321 996 $aImagining insiders$91297249 997 $aUNINA LEADER 07176nam 2200433 450 001 9910583347503321 005 20230120003614.0 010 $a0-12-814040-2 035 $a(CKB)5120000000096308 035 $a(MiAaPQ)EBC5558156 035 $a(Au-PeEL)EBL5558156 035 $a(OCoLC)1059413691 035 $a(EXLCZ)995120000000096308 100 $a20181119d2019 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aVaccines for cancer immunotherapy $ean evidence-based review on current status and future perspectives /$fNima Rezaei, Mahsa Keshavarz-Fathi 210 1$aLondon, United Kingdom :$cAcademic Press, an imprint of Elsevier,$d[2019] 210 4$dİ2019 215 $a1 online resource (185 pages) 311 $a0-12-814039-9 327 $aFront Cover -- Vaccines for Cancer Immunotherapy -- Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives -- Copyright -- Contents -- List of Contributors -- Preface -- 1 - CANCER IMMUNOLOGY -- INNATE AND ADOPTIVE IMMUNITY -- ACTIVATING IMMUNE CELLS -- MATURE DCS -- CLASSICALLY ACTIVATED MACROPHAGES (M1) -- GRANULOCYTES -- B LYMPHOCYTES -- T HELPER LYMPHOCYTES -- CYTOTOXIC T LYMPHOCYTES -- ?? T LYMPHOCYTES -- NATURAL KILLER T CELLS -- NATURAL KILLER CELLS -- INHIBITORY IMMUNE CELLS -- TOLEROGENIC DCS -- ALTERNATIVELY ACTIVATED MACROPHAGES (M2S) -- MYELOID-DERIVED SUPPRESSOR CELLS -- REGULATORY T CELLS -- REGULATORY B CELLS -- IMMUNOEDITING HYPOTHESIS -- ELIMINATION -- Cells -- Interferons -- Perforin -- Tumor Cell Recognition -- EQUILIBRIUM -- ESCAPE -- Defects in Tumor Antigen Processing, Presentation, and Recognition -- Lack of Activating Mechanisms -- Inhibitory Mechanisms and Immunosuppressive State -- Resistant Tumor Cells -- REFERENCES -- 2 - IMMUNOTHERAPEUTIC APPROACHES IN CANCER -- HISTORY -- APPROACHES OF CANCER IMMUNOTHERAPY -- PASSIVE VERSUS ACTIVE IMMUNOTHERAPY -- PASSIVE IMMUNOTHERAPY FOR CANCER -- Cytokines -- Monoclonal Antibodies (mAbs) -- Adoptive Cell Therapy -- ACTIVE IMMUNOTHERAPY FOR CANCER -- Vaccines -- Peptide Vaccine -- Tumor Cell Vaccine -- Dendritic Cell Vaccine -- Genetic Vaccine -- Checkpoint Inhibitors -- Oncolytic Viruses -- MECHANISM-BASED IMMUNOTHERAPIES: INTERACTIONS BETWEEN TUMOR CELLS AND THE IMMUNE SYSTEM -- TUMOR ANTIGEN EXPRESSION, RELEASE AND PRESENTATION -- T CELL PRIMING AND ACTIVATION -- TRAFFICKING AND INFILTRATION OF T CELLS TO TUMOR -- TUMOR CELL RECOGNITION AND EFFECTOR FUNCTION OF T CELLS -- REFERENCES -- 3 - VACCINES, ADJUVANTS, AND DELIVERY SYSTEMS -- DEFINITION AND CLASSIFICATION -- CANCER VACCINE -- PREVENTIVE CANCER VACCINE. 327 $aTHERAPEUTIC CANCER VACCINE -- ADJUVANTS -- NONSPECIFIC ADJUVANTS -- CYTOKINES AND CHEMOKINES -- STIMULATORS OF THE INNATE IMMUNE SYSTEM -- C-type Lectin Receptor Ligands -- RIG-like Receptor Ligands -- Stimulator of Interferon Gene Ligands -- Toll like Receptor Ligands -- TLR2 Agonists -- TLR3 Agonists -- TLR4 Agonists -- TLR7 and TLR8 Agonists -- TLR9 Agonists -- Other Immunomodulatory Adjuvants -- Adjuvant Systems -- VECTORS AND DELIVERY SYSTEM -- ROUTE OF ADMINISTRATION -- REFERENCES -- 4 - TUMOR ANTIGENS -- INTRODUCTION -- IDENTIFICATION OF TUMOR ANTIGENS -- OVEREXPRESSED PROTEINS AND MUTATED ANTIGENS IN TUMOR CELLS -- EPITOPE SPREADING -- TUMOR-ASSOCIATED ANTIGENS -- TUMOR-SPECIFIC ANTIGENS -- NEOANTIGENS -- GLYCOLIPIDS AND GLYCOPROTEINS AS ANTIGENS -- MONO-EPITOPE VERSUS POLY-EPITOPE ANTIGEN -- REFERENCES -- 5 - STRATEGY OF ALLOGENEIC AND AUTOLOGOUS CANCER VACCINES -- AUTOLOGOUS CANCER VACCINES -- IN VIVO STUDIES AND CLINICAL IMPLICATIONS -- ALLOGENEIC CANCER VACCINES -- IN VITRO/IN VIVO STUDIES AND CLINICAL IMPLICATIONS -- REFERENCES -- 6 - PERSONALIZED CANCER VACCINE -- INTRODUCTION ON PERSONALIZED MEDICINE -- PERSONALIZED MEDICINE IN CANCER PATIENTS -- SCREENING OF CANCER -- CLASSIFICATION OF TUMORS -- TARGETED THERAPY AND USING PREDICTIVE BIOMARKERS -- SAFETY OF MEDICATION -- PROGNOSTIC BIOMARKERS -- NEOANTIGENS AND PERSONALIZED CANCER VACCINES -- PERSONALIZED CANCER VACCINES IN CLINICAL STUDIES -- WHOLE TUMOR CELL VACCINES -- PEPTIDE/PROTEIN-BASED VACCINE -- IMMUNE CELL-BASED VACCINES -- GENETIC-BASED VACCINE -- REFERENCES -- 7 - WHOLE TUMOR CELL VACCINE FOR CANCER -- TUMOR CELL LYSATES -- TUMOR-DERIVED EXOSOMES -- IRRADIATED GENE-MODIFIED TUMOR CELL VACCINE -- CLINICAL TRIALS -- APPROVED VACCINE -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 8 - PEPTIDE AND PROTEIN VACCINES FOR CANCER -- PEPTIDE-BASED VACCINE. 327 $aPROTEIN-BASED VACCINE -- MECHANISM OF ACTION -- CLINICAL TRIALS -- PEPTIDE-BASED VACCINE -- Gp100 -- BLP25 -- PROTEIN BASED VACCINE -- MAGE-A3 -- EGF-P64k -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 9 - IMMUNE CELL VACCINE FOR CANCER -- IMMUNE CELL VACCINE -- MECHANISM OF ACTION -- CLINICAL TRIALS -- IMMATURE DENDRITIC CELLS PULSED WITH TUMOR CELL LYSATES -- MATURE DENDRITIC CELLS PULSED WITH TUMOR CELL LYSATES -- DENDRITIC CELLS LOADED WITH TUMOR-DERIVED RNA -- DENDRITIC CELLS PULSED WITH PEPTIDES -- DENDRITIC CELLS LOADED WITH TUMOR CELLS -- APPROVED VACCINE -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 10 - GENETIC VACCINE FOR CANCER -- MECHANISM OF ACTION -- MECHANISM OF ACTION OF DNA VACCINES -- MECHANISM OF ACTION OF RNA VACCINES -- DNA VACCINE -- CLINICAL TRIALS -- DELIVERY, IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE EFFECTS -- RNA VACCINE -- CLINICAL TRIALS -- DELIVERY, IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE EFFECTS -- ADVANTAGES AND DISADVANTAGES -- ADVANTAGES AND DISADVANTAGES OF DNA VACCINES -- ADVANTAGES OF RNA VACCINES -- OPTIMIZATION -- DNA VACCINE OPTIMIZATION -- RNA VACCINE OPTIMIZATION -- REFERENCES -- 11 - CANDIDATE CANCERS FOR VACCINATION -- VACCINES FOR PROSTATE CANCER -- VACCINES FOR MELANOMA -- VACCINES FOR LUNG CANCER -- VACCINES FOR COLORECTAL CANCER -- VACCINES FOR BREAST CANCER -- REFERENCES -- 12 - OBSTACLES IN THE DEVELOPMENT OF THERAPEUTIC CANCER VACCINES -- TUMOR ANTIGENS -- TUMOR BURDEN -- CLINICAL RESPONSE VERSUS IMMUNE RESPONSE -- PRIOR TREATMENTS -- DESIGNING CLINICAL TRIALS -- REFERENCES -- 13 - COMBINATION THERAPY: CANCER VACCINES AND OTHER THERAPEUTICS -- CHEMOTHERAPY COMBINED WITH VACCINES -- RADIATION COMBINED WITH VACCINES -- TARGETED THERAPIES COMBINED WITH IMMUNOTHERAPY -- HORMONE THERAPY COMBINED WITH VACCINE. 327 $aVACCINE COMBINED WITH OTHER IMMUNOTHERAPEUTIC MODALITIES -- REFERENCES -- 14 - CONCLUDING REMARKS AND FUTURE PERSPECTIVES ON THERAPEUTIC CANCER VACCINES -- CONCLUDING REMARKS -- BASIC IMMUNOLOGY OF CANCER VACCINES -- APPROVED VACCINES -- NEOANTIGEN VACCINES -- PREVENTIVE CANCER VACCINE -- CONSIDERATIONS TO FULFILL AMBITIONS -- REFERENCES -- Index -- Back Cover. 606 $aCancer$xImmunotherapy 615 0$aCancer$xImmunotherapy. 676 $a616.994061 700 $aRezaei$b Nima$0913363 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910583347503321 996 $aVaccines for cancer immunotherapy$92271400 997 $aUNINA